ATE396186T1
Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
Abstract
Tetrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
Term
Term ended
Projected expiry passed 1 October 2022, 4 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
1 priority claim, no other members on record
Priority claims1
| Document | Office | Kind | Date |
|---|---|---|---|
| 32713201 | United States of America | P |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Ceased as to paragraph 5 lit. 3 law introducing patent treatiesCeasedRER | RER |
Numbers
- Application
- 2776076
Titles2
- German
- HETEROARYLSUBSTITUIERTE TETRAZOLMODULATOREN DES METABOTROPISCHEN GLUTAMATREZEPTORS-5
- English
- HETEROARYL-SUBSTITUTED TETRAZOL MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR-5
Classification
- CPC, 23
- C07D401/14
- C07D401/04
- C07D403/04
- C07D403/14
- C07D405/04
- C07D405/14
- C07D413/04
- C07D417/04
- C07D417/14
- C07D471/04
- A61P25/04
- A61P25/08
- A61P25/14
- A61P25/16
- A61P25/18
- A61P25/20
- A61P25/22
- A61P25/24
- A61P25/28
- A61P25/30
- A61P25/34
- A61P29/00
- A61P3/04
- IPC, 36
- A61K31 135
- A61K31 4155
- A61K31 4178
- A61K31 4184
- A61K31 42
- A61K31 422
- A61K31 4439
- A61K31 4709
- A61K31 4725
- A61K31 485
- A61K31 497
- A61K45 00
- A61P3 04
- A61P25 04
- A61P25 08
- A61P25 14
- A61P25 16
- A61P25 18
- A61P25 20
- A61P25 22
- A61P25 24
- A61P25 28
- A61P25 30
- A61P25 34
- A61P29 00
- C07D401 04
- C07D401 14
- C07D403 04
- C07D403 14
- C07D405 04
- C07D405 14
- C07D413 04
- C07D413 14
- C07D417 04
- C07D417 14
- C07D471 04